When Sweating Signals a Health Issue: Know When to Seek Help

When Sweating Signals a Health Issue: Know When to Seek Help

Sweating is an essential physiological mechanism for thermoregulation, but when it becomes excessive, nocturnal, or occurs in atypical patterns, it may signal an underlying pathological condition. The differential diagnosis for pathological sweating is broad, encompassing endocrinological, neurological, infectious, and malignant etiologies. Among these, infectious causes have gained increasing attention, particularly the potential link between chronic infections such as Lyme borreliosis and unexplained sweating episodes. This article examines the epidemiology, pathophysiology, and clinical significance of sweating as a symptom, with particular emphasis on when it warrants medical investigation and the potential role of Borrelia species in producing this manifestation.

The Epidemiology of Pathological Sweating

Pathological sweating, including hyperhidrosis and night sweats, affects a substantial proportion of the population across all age groups. Epidemiological studies estimate that primary hyperhidrosis affects approximately 2.8 percent of the United States population, though this figure likely underestimates the true prevalence due to underreporting and misdiagnosis. Night sweats, defined as drenching perspiration that soaks through clothing and bedding, are even more common, with prevalence rates ranging from 10 to 41 percent in primary care populations depending on the diagnostic criteria employed. The wide variation in reported prevalence reflects differences in study design, population demographics, and the lack of standardized definitions for what constitutes clinically significant night sweats.

Age and sex are significant demographic factors in the epidemiology of sweating disorders. Women of perimenopausal and menopausal age experience vasomotor symptoms including hot flushes and night sweats at rates exceeding 60 to 80 percent in Western populations. As Deecher and Dorries have elucidated in their comprehensive review of vasomotor symptom pathophysiology, these symptoms result from complex neuroendocrine changes involving estrogen withdrawal, altered thermoregulatory set points, and dysregulation of hypothalamic neurotransmitters. The duration of these symptoms is highly variable, with Avis and colleagues demonstrating in their longitudinal study published in JAMA Internal Medicine that vasomotor symptoms persist for a median of 7.4 years, with some women experiencing symptoms for more than a decade after their final menstrual period.

In men, pathological sweating is less commonly attributed to hormonal changes but may signal underlying conditions such as hypogonadism, hyperthyroidism, or infectious processes. The sex distribution of sweating disorders is therefore bimodal, with a female predominance during reproductive transitions and a more equal distribution across sexes for infectious and malignant causes. Racial and ethnic differences also exist, with African American women reporting higher rates of vasomotor symptoms compared to Caucasian and Asian populations, though the biological mechanisms underlying these disparities remain incompletely understood.

Infectious Etiologies of Sweating and Their Epidemiological Patterns

Infectious diseases represent a significant cause of pathological sweating, particularly when the sweating occurs at night or is accompanied by fever, chills, and constitutional symptoms. The classic infectious causes of night sweats include tuberculosis, which remains a leading cause of morbidity and mortality worldwide, with an estimated 10.6 million cases and 1.3 million deaths in 2022 according to World Health Organization data. Tuberculosis-associated night sweats result from the host inflammatory response to Mycobacterium tuberculosis, with cytokines such as tumor necrosis factor-alpha and interleukin-1 acting on the hypothalamic thermoregulatory center to produce fever and diaphoresis.

Other bacterial infections associated with pathological sweating include brucellosis, which is endemic in the Mediterranean basin, the Middle East, and parts of Latin America, where it causes undulant fever accompanied by profuse sweating. Infective endocarditis, particularly when caused by viridans group streptococci or Staphylococcus aureus, can present with night sweats as a cardinal manifestation, reflecting the continuous bacteremia and systemic inflammatory response. Viral infections including human immunodeficiency virus (HIV), Epstein-Barr virus, and cytomegalovirus can also produce sweating abnormalities, particularly during the acute seroconversion phase or in the context of opportunistic infections in immunocompromised hosts.

Fungal infections such as histoplasmosis and coccidioidomycosis, which are geographically restricted to specific regions of North and South America, can mimic tuberculosis with night sweats, cough, and constitutional symptoms. The epidemiological patterns of these infections are closely tied to environmental exposure, with Histoplasma capsulatum found in soil enriched with bat or bird droppings in the Ohio and Mississippi River valleys, and Coccidioides immitis endemic to the arid soils of the southwestern United States and northern Mexico. Clinicians must therefore consider geographic exposure history when evaluating patients with unexplained sweating.

Lyme Borreliosis and Sweating: An Underrecognized Association

The potential link between Borrelia burgdorferi infection and pathological sweating has received increasing attention in the Lyme disease literature, though it remains an area of ongoing investigation and debate. Lyme disease, caused by Borrelia burgdorferi sensu lato complex in North America and Borrelia afzelii and Borrelia garinii in Europe and Asia, is the most common vector-borne disease in the Northern Hemisphere. The Centers for Disease Control and Prevention estimates that approximately 476,000 Americans are diagnosed and treated for Lyme disease annually, though true incidence may be substantially higher due to underreporting and diagnostic challenges.

Sweating abnormalities in Lyme disease can manifest in several ways. During the early disseminated phase, which occurs weeks to months after the initial tick bite, patients may experience intermittent fevers, chills, and drenching night sweats as part of the systemic inflammatory response to spirochetal dissemination. These symptoms are often accompanied by migratory arthralgias, myalgias, fatigue, and cognitive dysfunction, creating a clinical picture that can be mistaken for viral illness or autoimmune disease. In chronic or persistent Lyme disease, which some researchers refer to as post-treatment Lyme disease syndrome, night sweats may persist or recur months to years after initial antibiotic therapy, suggesting ongoing immune dysregulation or persistent infection in protected niches.

The pathophysiology of Borrelia-associated sweating is multifactorial. The spirochete itself produces lipoproteins that activate Toll-like receptors on macrophages and dendritic cells, triggering a cascade of proinflammatory cytokines including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. These cytokines act directly on the hypothalamus to reset the thermoregulatory set point, producing fever and sweating. Additionally, Borrelia species have been shown to invade and persist within neural tissue, potentially disrupting autonomic nervous system function and leading to dysregulation of sweat gland innervation. The sympathetic nervous system, which controls eccrine sweat gland secretion, can be affected by Borrelia-induced neuroinflammation, resulting in either hyperhidrosis or anhidrosis depending on the pattern of neural involvement.

Epidemiological studies examining the prevalence of sweating in Lyme disease patients have yielded variable results. In prospective cohort studies of early Lyme disease, approximately 30 to 50 percent of patients report fever and chills, with a smaller proportion describing night sweats as a prominent symptom. In chronic Lyme disease cohorts, the prevalence of night sweats may be higher, with some case series reporting rates exceeding 60 percent. However, these figures must be interpreted cautiously due to selection bias in referral populations and the lack of standardized diagnostic criteria for chronic Lyme disease. Population-based studies using validated symptom questionnaires and rigorous case definitions are needed to establish the true prevalence of sweating abnormalities in Borrelia-infected populations.

Neoplastic and Paraneoplastic Causes of Sweating

Malignancy represents a critical differential diagnosis in patients presenting with unexplained sweating, particularly when the sweating is nocturnal, drenching, and accompanied by weight loss, fever, or lymphadenopathy. Lymphomas, both Hodgkin and non-Hodgkin types, are classically associated with night sweats as part of the B-symptom complex, which also includes unexplained fever and weight loss exceeding 10 percent of body weight over six months. The prevalence of night sweats in Hodgkin lymphoma at diagnosis ranges from 25 to 40 percent, and their presence carries prognostic significance, with B-symptom positive patients having worse outcomes compared to those without constitutional symptoms.

Other hematological malignancies associated with pathological sweating include leukemia, particularly acute myeloid leukemia and chronic lymphocytic leukemia, as well as myeloproliferative neoplasms such as polycythemia vera and essential thrombocythemia. The mechanisms underlying malignancy-associated sweating are incompletely understood but likely involve tumor-derived cytokines, including interleukin-1, interleukin-6, and tumor necrosis factor-alpha, which act on the hypothalamus to produce fever and diaphoresis. Additionally, tumor necrosis and the host inflammatory response to malignant cells contribute to the metabolic derangements that trigger sweating.

Solid tumors can also produce sweating as a paraneoplastic phenomenon, particularly neuroendocrine tumors such as carcinoid tumors and pheochromocytomas. Carcinoid tumors, which arise from enterochromaffin cells in the gastrointestinal tract or bronchial tree, secrete vasoactive substances including serotonin, histamine, and bradykinin that can cause flushing and sweating, particularly when liver metastases allow these substances to reach the systemic circulation. Pheochromocytomas, catecholamine-secreting tumors of the adrenal medulla, produce episodic hypertension, palpitations, and profuse diaphoresis due to the direct effects of epinephrine and norepinephrine on sweat gland stimulation and thermoregulation.

The epidemiological patterns of malignancy-associated sweating mirror those of the underlying cancers. Hodgkin lymphoma has a bimodal age distribution with peaks in young adulthood (ages 15 to 35) and older adulthood (over age 55), while non-Hodgkin lymphoma incidence increases with age. Neuroendocrine tumors are rare, with an incidence of approximately 6 to 7 cases per 100,000 person-years in the United States, but their prevalence is increasing due to improved diagnostic imaging and incidental detection. Pheochromocytomas are even rarer, occurring in approximately 0.1 to 0.2 percent of patients with hypertension, but their recognition is critical due to the potential for life-threatening hypertensive crises.

Endocrinological and Metabolic Causes of Sweating

Endocrine disorders represent another major category of conditions that can present with pathological sweating. Hyperthyroidism, whether due to Graves disease, toxic nodular goiter, or thyroiditis, is a classic cause of generalized hyperhidrosis. The prevalence of hyperthyroidism in the general population is approximately 1.3 percent in iodine-sufficient regions, with a strong female predominance and peak incidence between the ages of 30 and 60 years. The excessive sweating in hyperthyroidism results from increased basal metabolic rate, enhanced thermogenesis, and heightened sympathetic nervous system activity driven by elevated thyroid hormone levels. Patients typically describe feeling constantly warm and sweating profusely even in cool environments, often accompanied by heat intolerance, weight loss despite increased appetite, palpitations, and tremor.

Diabetes mellitus, particularly when poorly controlled, can produce sweating abnormalities through multiple mechanisms. Autonomic neuropathy, a common complication of long-standing diabetes, can disrupt the sympathetic innervation of sweat glands, leading to either hyperhidrosis or anhidrosis depending on the pattern of nerve fiber involvement. Gustatory sweating, known as Frey syndrome, occurs in some diabetic patients and involves profuse facial sweating triggered by eating, particularly spicy foods. The prevalence of autonomic neuropathy in diabetic populations ranges from 20 to 60 percent depending on disease duration and glycemic control, and its presence is associated with increased cardiovascular mortality. Additionally, hypoglycemic episodes in diabetic patients, whether due to insulin therapy or oral hypoglycemic agents, produce characteristic adrenergic symptoms including sweating, palpitations, and tremor as the body attempts to raise blood glucose levels through counterregulatory hormone release.

Hypogonadism in men, characterized by low testosterone levels, can produce vasomotor symptoms including hot flushes and night sweats that are analogous to those experienced by menopausal women. The prevalence of hypogonadism increases with age, affecting approximately 20 percent of men over age 60 and 50 percent of men over age 80. The sweating in hypogonadism results from the loss of testosterone-mediated negative feedback on the hypothalamus, leading to increased gonadotropin-releasing hormone pulsatility and altered thermoregulation. Similarly, women undergoing menopause experience vasomotor symptoms due to estrogen withdrawal and altered hypothalamic thermoregulatory set points, as described by Deecher and Dorries. The Study of Women's Health Across the Nation (SWAN) has provided extensive epidemiological data on the natural history of vasomotor symptoms, demonstrating that their prevalence peaks during the late perimenopause and early postmenopause periods and that risk factors include higher body mass index, smoking, and lower educational attainment.

Other metabolic causes of sweating include pheochromocytoma, as previously discussed, as well as carcinoid syndrome, mastocytosis, and insulinoma. Mastocytosis, a rare disorder characterized by abnormal accumulation of mast cells in tissues, can produce episodic flushing, sweating, and hypotension due to mast cell degranulation and release of histamine, tryptase, and other vasoactive mediators. The prevalence of mastocytosis is estimated at 1 to 10 cases per 100,000 population, with cutaneous mastocytosis being more common in children and systemic mastocytosis more common in adults.

Neurological and Autonomic Causes of Sweating

Neurological disorders that affect the autonomic nervous system can produce profound sweating abnormalities. Primary autonomic failure syndromes, including multiple system atrophy, pure autonomic failure, and Parkinson disease with autonomic involvement, can cause both hyperhidrosis and anhidrosis depending on the pattern of neural degeneration. Multiple system atrophy, a rare neurodegenerative disorder with an estimated prevalence of 3 to 5 cases per 100,000 population, is characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia. Patients with multiple system atrophy often experience severe orthostatic hypotension, urinary retention, and thermoregulatory dysfunction including both excessive sweating and heat intolerance due to impaired sweating.

Peripheral neuropathies, whether due to diabetes, alcoholism, amyloidosis, or autoimmune conditions such as Guillain-Barre syndrome, can disrupt the postganglionic sympathetic fibers that innervate eccrine sweat glands. The resulting pattern of sweating abnormalities depends on the distribution and severity of nerve fiber involvement. In diabetic autonomic neuropathy, for example, patients may develop anhidrosis in the lower extremities with compensatory hyperhidrosis in the upper body, leading to a characteristic pattern of drenching upper body sweating during exercise or heat exposure. The prevalence of peripheral neuropathy in diabetic populations is substantial, affecting approximately 30 to 50 percent of patients with long-standing disease.

Focal hyperhidrosis, which affects specific body regions such as the palms, soles, axillae, or face, is thought to result from localized autonomic hyperactivity. The prevalence of primary focal hyperhidrosis is estimated at 2.8 percent in the United States, with onset typically occurring in childhood or adolescence. The condition is not merely a cosmetic concern but can significantly impair quality of life, affecting social interactions, occupational performance, and psychological well-being. The pathophysiology involves hyperstimulation of eccrine sweat glands by the sympathetic nervous system, though the exact mechanisms remain unclear. Genetic factors play a role, with family history present in 30 to 50 percent of cases, suggesting an autosomal dominant inheritance pattern with variable penetrance.

Cholinergic urticaria, a condition characterized by the development of small, intensely pruritic wheals in response to sweating, represents a distinct subtype of physical urticaria. As Fukunaga and colleagues have described in their comprehensive review published in the American Journal of Clinical Dermatology, cholinergic urticaria can be classified into several subtypes based on the underlying mechanism, including sweat allergy type, where patients develop hypersensitivity to their own sweat, and hypohidrotic type, where reduced sweating capacity leads to cholinergic stimulation and mast cell degranulation. The prevalence of cholinergic urticaria is estimated at 5 to 7 percent of patients with chronic urticaria, with onset typically in young adulthood and a slight male predominance.

Pharmacological and Toxicological Causes of Sweating

Numerous medications can induce sweating as an adverse effect, and this iatrogenic cause must be considered in the differential diagnosis of pathological sweating. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are among the most common drug classes associated with hyperhidrosis. The prevalence of SSRI-induced sweating varies across studies but has been reported in 5 to 20 percent of treated patients, with higher rates associated with higher doses and longer treatment duration. The mechanism involves serotonergic modulation of hypothalamic thermoregulatory centers, leading to altered set points and inappropriate sweating responses.

Other medications associated with pathological sweating include antipyretics such as acetaminophen and nonsteroidal anti-inflammatory drugs, which can produce rebound sweating as their effects wear off; hormonal therapies including tamoxifen and gonadotropin-releasing hormone agonists, which induce vasomotor symptoms through estrogen modulation; and cholinesterase inhibitors used in Alzheimer disease, which enhance cholinergic transmission and can stimulate sweat gland secretion. Opioid withdrawal, whether from prescribed pain medications or illicit substances, produces characteristic symptoms including profuse sweating, piloerection, mydriasis, and gastrointestinal distress, reflecting the rebound hyperactivity of the autonomic nervous system following chronic opioid receptor stimulation.

Toxicological causes of sweating include poisoning with organophosphate insecticides, which irreversibly inhibit acetylcholinesterase and lead to cholinergic crisis characterized by excessive salivation, lacrimation, urination, defecation, gastrointestinal distress, and sweating (the SLUDGE syndrome). Heavy metal poisoning, particularly with mercury or arsenic, can produce peripheral neuropathy and autonomic dysfunction with associated sweating abnormalities. The epidemiological patterns of these toxicological causes are closely tied to occupational and environmental exposures, with agricultural workers being at highest risk for organophosphate poisoning and individuals with occupational or dietary exposure to contaminated seafood or industrial waste being at risk for heavy metal toxicity.

When to Seek Medical Evaluation for Sweating

Determining when pathological sweating warrants medical evaluation requires consideration of the symptom's severity, duration, associated features, and the patient's demographic and clinical context. Night sweats that are drenching, requiring a change of clothing or bedding, occurring for more than two weeks, or accompanied by unexplained fever, weight loss, fatigue, or lymphadenopathy should prompt medical investigation. The presence of these B-symptoms raises concern for underlying malignancy, chronic infection, or autoimmune disease and warrants a thorough diagnostic workup including complete blood count, comprehensive metabolic panel, inflammatory markers, infectious disease serologies, and imaging studies as clinically indicated.

In patients with known or suspected tick exposure, particularly those residing in or traveling to Lyme-endemic regions of the northeastern, mid-Atlantic, or upper midwestern United States, or in Central Europe and Scandinavia, the development of night sweats should raise suspicion for Borrelia infection. The classic erythema migrans rash, which appears in 70 to 80 percent of Lyme disease cases, provides a valuable diagnostic clue, but its absence does not rule out infection, as the rash can be atypical, transient, or located in hidden areas. Patients with unexplained sweating in the context of tick exposure, particularly when accompanied by migratory arthralgias, myalgias, cognitive dysfunction, or facial nerve palsy, should undergo serological testing for Lyme disease using the two-tier testing algorithm recommended by the Centers for Disease Control and Prevention.

It is important to recognize that standard Lyme disease tests have significant limitations. The enzyme-linked immunosorbent assay (ELISA) and Western blot tests rely on the detection of antibodies produced by the host immune system, which may not be present during the first several weeks of infection or in patients with early antibiotic treatment. Furthermore, Borrelia species have evolved sophisticated immune evasion mechanisms, including antigenic variation, complement evasion, and the ability to form biofilm-like structures and round body forms that may reduce the host antibody response. As a result, false-negative serology is a well-documented phenomenon, particularly in patients with chronic or disseminated infection. Clinicians should therefore maintain a high index of suspicion for Lyme disease in patients with compatible clinical presentations and exposure history, even when initial serological testing is negative.

In patients presenting with focal hyperhidrosis, particularly when onset is in childhood or adolescence and symptoms are localized to the palms, soles, or axillae, primary hyperhidrosis is the most likely diagnosis. However, secondary causes including hyperthyroidism, diabetes, and neurological disorders should be excluded through appropriate laboratory testing and clinical evaluation. The Hyperhidrosis Disease Severity Scale provides a validated tool for assessing symptom severity and treatment response, with scores of 3 or 4 indicating severe hyperhidrosis that warrants intervention.

Patients with vasomotor symptoms in the context of perimenopause or menopause should be evaluated for the severity and impact of their symptoms on quality of life, with consideration of hormone therapy or nonhormonal interventions for those with moderate to severe symptoms. The duration of vasomotor symptoms is highly variable, as demonstrated by Avis and colleagues, and shared decision-making regarding treatment options should incorporate the patient's preferences, risk factors, and treatment goals.

Conclusion and Public Health Implications

Pathological sweating represents a common and often underappreciated clinical symptom with a broad differential diagnosis spanning infectious, neoplastic, endocrinological, neurological, and pharmacological causes. The epidemiological patterns of sweating disorders are heterogeneous, with prevalence varying by age, sex, geographic region, and underlying etiology. Among infectious causes, Lyme borreliosis deserves particular attention due to its high prevalence in endemic regions, its protean clinical manifestations, and the potential for misdiagnosis when sweating is the presenting symptom.

The public health implications of unrecognized Borrelia infection are substantial. Delayed or missed diagnosis of Lyme disease can lead to progression from early localized to disseminated infection, with involvement of the nervous system, joints, heart, and other organs. Chronic Lyme disease, whether due to persistent infection, autoimmune phenomena, or post-infectious sequelae, is associated with significant morbidity, reduced quality of life, and substantial healthcare utilization. Improved awareness among clinicians and the public regarding the potential link between sweating abnormalities and Lyme disease could facilitate earlier diagnosis and treatment, potentially reducing the burden of chronic complications.

Future research should focus on establishing standardized diagnostic criteria for pathological sweating, conducting population-based epidemiological studies to determine the true prevalence of sweating in various disease states, and developing more sensitive and specific diagnostic tests for Borrelia infection. The role of Borrelia species in producing autonomic dysfunction and sweating abnormalities warrants further investigation through prospective cohort studies, case-control studies, and basic science research examining the mechanisms of spirochetal neuroinvasion and immune evasion. Only through such comprehensive research efforts can we fully understand the clinical significance of sweating as a signal of underlying health issues and develop evidence-based guidelines for when to seek medical help.